童喘清颗粒治疗哮喘缓解期患儿60例临床研究

发布时间：2018-07-11 18:47

本文选题：童喘清颗粒 + 哮喘缓解期　；参考：《湖北中医药大学》2012年硕士论文

【摘要】：目的哮喘是小儿时期常见的中医肺系疾病,是一种反复发作的痰鸣气喘疾病。目前哮喘已是一个全球关注的公共健康问题,也是儿童至成人期最常见的慢性疾病。儿童哮喘如果不及时诊治,严重者有可能因缺氧导致呼吸困难甚至窒息,后果不堪设想。因哮喘缓解期患儿无疾病相关症状或症状轻微,尽量长时间的维持在此阶段是医师和患者的共同目标,所以保持在缓解期预防发作是哮喘最关键的治疗环节。我们以益气培元,平喘止咳,化痰下气为法,观察童喘清颗粒治疗哮喘缓解期虚哮证的疗效。方法 60例哮喘缓解期患儿采用分层区组随机设计法,分为实验组与对照组,每组各30例。分两级设盲：一级设盲以A组、B组表示,二级设盲再分别指定A组、B组的实验组、对照组的归属。实验组(A组)予童喘清颗粒,规格：颗粒剂,3g/袋。对照组(B组)予安慰剂,规格：颗粒剂,3g/袋。外包装、颜色、气味等应尽可能与原制剂相同。试验时间为4周±4天,患儿服药期间每周访视1次,观察患儿日间症状,夜间症状/憋醒,活动受限、咳嗽、自汗、面色少华、神疲懒言、舌象、脉象及肺功能等变化,并观察服药后不良反应。控制病例临床用药结束后满12周±6天进行随访,再次评估哮喘控制情况。结果试验组总临床控制率79.31%,总有效率96.55%；对照组临床控制率32.14%,总有效率53.57%；两组差异有统计学意义(P0.05)。结论童喘清颗粒可以缓解患儿临床缓解期症状,改善肺通气功能,对哮喘缓解期虚哮证患儿有明显疗效,其作用机理与减轻气道阻塞,调节免疫反应及抑制气道炎症等多个环节有关。
[Abstract]:Objective Asthma is a common disease of traditional Chinese medicine (TCM) in infantile period, and it is a recurrent disease of phlegm and asthma. Asthma is now a global public health concern and the most common chronic disease in childhood and adulthood. If children's asthma is not treated in time, severe asthma may lead to breathing difficulties or even suffocation due to hypoxia, and the consequences are unthinkable. Since there are no disease related symptoms or mild symptoms in children with asthma remission, it is the common goal of doctors and patients to maintain it for as long as possible, so it is the most important treatment link to maintain the prevention of asthma in remission period. We observed the curative effect of Tongchuanqing granule on asthmatic asthenia syndrome in remission period with Yiqi Peiyuan, relieving asthma and relieving cough and eliminating phlegm and qi. Methods 60 children with asthma in remission period were randomly divided into experimental group and control group with 30 cases in each group. There were two levels of blindness: the first set of blindness was indicated by group A and group B, and the second group was assigned to the experimental group and the control group respectively. The experimental group (group A) was given Tongchuanqing granules, specifications: granules 3 g / bag. Control group (group B) was given placebo, specification: granule 3 g / bag. Packaging, color, odour, etc should be as much as possible the same as the original preparation. The test time was 4 weeks 卤4 days. The children were visited once a week during taking medicine. The changes of daytime symptoms, nocturnal symptoms / suffocations, restricted activities, cough, self-sweating, complexion, fatigue, tongue, pulse and lung function were observed. Adverse reactions were observed. The control cases were followed up for 12 weeks 卤6 days after the end of drug administration, and the control status of asthma was evaluated again. Results the total clinical control rate of the experimental group was 79.31 and the total effective rate was 96.555.The clinical control rate of the control group was 32.14 and the total effective rate was 53.57. The difference between the two groups was statistically significant (P0.05). Conclusion Tongchuanqing granule can relieve clinical symptoms and improve pulmonary ventilation function in children with asthmatic asthenia. Regulation of immune response and inhibition of airway inflammation and other links related.
【学位授予单位】：湖北中医药大学
【学位级别】：硕士
【学位授予年份】：2012
【分类号】：R272

【参考文献】